Zapping the brain to understand schizophrenia: small study tests TMS on attention and cravings
NCT ID NCT07190352
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This completed study tested whether targeted brain stimulation (TMS) could affect attention and nicotine cravings in 15 people with schizophrenia or schizoaffective disorder who smoke. Researchers applied different types of TMS to a brain network linked to attention and measured changes in brain connectivity and craving levels. The goal was to understand how brain networks work in schizophrenia, not to provide a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- transcranial magnetic stimulation (TMS)
- What this could lead to
- If successful, this could help researchers understand how brain networks affect attention and cravings in schizophrenia, potentially guiding future treatments.
- What could go wrong
- This is a very small, early-stage study with only 15 participants. It was designed to explore brain activity, not to test a treatment, so results may not lead to any direct benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Oct 2021
- Finished
-
Oct 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18-65 years * At pre-visit screening (see attached phone screening questionnaire): Subjects must report that they have been given a diagnosis of schizophrenia or schizoaffective disorder by a mental health professional * Current smoker (expired air CO of 5ppm or higher) * Must be able to read, speak and understand English * Must be judged by study staff to be capable of completing the study procedures * Diagnosis of either schizophrenia or schizoaffective disorder according to DSM-V criteria and confirmed by SCID\[26\] * Participants will be in stable outpatient treatment with no recent (within the past 30 days) hospitalizations or changes in their medication regimens. Exclusion Criteria: * DSM-V intellectual disability * Substance use disorder within the past three months * Any history of a progressive or genetic neurologic disorder (e.g. Parkinson's disease, multiple sclerosis, tuberous sclerosis, Alzheimer's Disease) or acquired neurological disease (e.g. stroke, traumatic brain injury, tumor), including intracranial lesions * History of head trauma resulting in any loss of consciousness (\>15 minutes) or neurological sequelae * Current history of poorly controlled headaches including chronic medication for migraine prevention * History of fainting spells of unknown or undetermined etiology that might constitute seizures * History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family history epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist * Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * Any metal in the brain or skull (excluding dental fillings) or elsewhere in the body unless cleared by the responsible covering MD (e.g. MRI compatible joint replacement) * Any devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible covering MD * All female participants of child-bearing age will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study * Medications will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and use of CNS active drugs. The published TMS guidelines review of medications to be considered with rTMS will be taken into consideration given their described effects on cortical excitability measures. * Any changes in medications or hospitalizations within the past 30 days. * Subjects who, in the investigator's opinion, might not be suitable for the study or would be unable to tolerate the study visit.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nicotine use are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists build a computer model of the brain to explain hearing voices
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug